95 related articles for article (PubMed ID: 34638422)
1. Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study.
Servetto A; Santaniello A; Napolitano F; Foschini F; Marciano R; Mozzillo E; Cascetta P; Amato AR; Augurio MR; Maresca L; De Placido P; De Placido S; Formisano L; Bianco R
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638422
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review.
Napolitano F; Formisano L; Giardino A; Girelli R; Servetto A; Santaniello A; Foschini F; Marciano R; Mozzillo E; Carratù AC; Cascetta P; De Placido P; De Placido S; Bianco R
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31337045
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity.
Zhang Y; Hochster H; Stein S; Lacy J
Exp Hematol Oncol; 2015; 4():29. PubMed ID: 26451276
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
5. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients.
Kieler M; Unseld M; Bianconi D; Schindl M; Kornek GV; Scheithauer W; Prager GW
J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32121198
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness and resource utilization of
Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
[TBL] [Abstract][Full Text] [Related]
7. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
Kunzmann V; Herrmann K; Bluemel C; Kapp M; Hartlapp I; Steger U
Case Rep Oncol; 2014 Sep; 7(3):648-55. PubMed ID: 25408659
[TBL] [Abstract][Full Text] [Related]
8. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N;
Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989
[TBL] [Abstract][Full Text] [Related]
9. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy.
Tong YT; Lai Z; Katz MHG; Prakash LR; Wang H; Chatterjee D; Kim M; Tzeng CD; Lee JE; Ikoma N; Rashid A; Wolff RA; Zhao D; Koay EJ; Maitra A; Wang H
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174073
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant nab-paclitaxel plus gemcitabine
Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going.
Coppola A; Farolfi T; La Vaccara V; Iannone I; Giovinazzo F; Panettieri E; Tarallo M; Cammarata R; Coppola R; Caputo D
J Clin Med; 2023 May; 12(11):. PubMed ID: 37297872
[TBL] [Abstract][Full Text] [Related]
12. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report.
Okura R; Takano S; Yokota T; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Miyazaki M; Ohtsuka M
Mol Clin Oncol; 2018 Oct; 9(4):389-393. PubMed ID: 30214727
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Pusceddu S; Ghidini M; Torchio M; Corti F; Tomasello G; Niger M; Prinzi N; Nichetti F; Coinu A; Di Bartolomeo M; Cabiddu M; Passalacqua R; de Braud F; Petrelli F
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30959763
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
Front Oncol; 2020; 10():41. PubMed ID: 32083002
[TBL] [Abstract][Full Text] [Related]
15. [Outcomes of FOLFIRINOX as First-Line Treatment for Recurrent or Unresectable Pancreatic Cancer].
Tsujie M; Fumita S; Ishikawa H; Kitani K; Satoi S; Fukuda S; Manabe H; Akashi Y; Wakasa T; Shiono H; Tamura T; Yukawa M; Inoue M
Gan To Kagaku Ryoho; 2019 Aug; 46(8):1259-1263. PubMed ID: 31501367
[TBL] [Abstract][Full Text] [Related]
16. Surgery for locally advanced pancreatic ductal adenocarcinoma-is it only about the vessels?
Heckler M; Hackert T
J Gastrointest Oncol; 2021 Oct; 12(5):2503-2511. PubMed ID: 34790411
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Treatment in Pancreatic Cancer.
Oba A; Ho F; Bao QR; Al-Musawi MH; Schulick RD; Del Chiaro M
Front Oncol; 2020; 10():245. PubMed ID: 32185128
[TBL] [Abstract][Full Text] [Related]
18. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer.
Takeda T; Sasaki T; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2021 Apr; 51(5):728-736. PubMed ID: 33611490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
